Sign in
Taking peoplePhase 3

Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults

Key facts

Who runs it
Brainfarma Industria Química e Farmacêutica S/A
Where
Brazil15 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
620 people, planned
Started
8 May 2026
Expected to end
30 Jun 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg
  • dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg
  • Placebo
Record updated
16 June 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • The following criteria must be met for the participant to be included in the study:; Participants of both sexes, aged between 18 and 60 years; Be able to understand, agree to participate in the study, comply with procedures, and attend visits, as indicated by signing the informed consent form (ICF) approved by the Ethics Committee; Present symptoms of nasal obstruction and/or congestion due to the common cold or influenza, with onset within less than 48 hours, with symptoms classified by the participant as moderate to severe on a 4-point scale (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms); Must not have used any medication for symptomatic treatment of the condition; Female participants without childbearing potential, defined as postmenopausal women (defined as 12 months or more of amenorrhea) or those who have undergone surgical sterilization*, OR female participants with reproductive potential who agree to use a reliable contraceptive method**; Female sterilization (bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation performed at least 6 weeks before administration of the investigational product; ** If the participant is of childbearing potential and decides to participate in the study, she must use or request that her partner use a reliable contraceptive method. Reliable contraception is defined as the use of at least one of the following: condoms, diaphragm, and/or hormonal contraceptive methods (estrogenic and/or progestogenic), including oral, vaginal, injectable, transdermal, implantable, and intrauterine devices. Only participants who explicitly declare no risk of pregnancy, either due to not engaging in sexual activity or engaging exclusively in non-reproductive practices, may participate without mandatory contraceptive use; for example: participants with a sterile or vasectomized partner (at least 6 months before screening), or total heterosexual abstinence

Who cannot take part

  • A positive response to any of the following criteria will exclude the participant from the study:; Participants with COVID-19, diagnosed by rapid antigen test and/or RT-PCR for SARS-CoV-2; Previous contact with individuals diagnosed with COVID-19 within 14 days prior to screening; Vaccination against influenza and/or COVID-19 within 7 days prior to the study; Presence of gastrointestinal symptoms and/or dyspnea associated with cold or flu symptoms; Clinical history consistent with bacterial upper respiratory tract infection requiring antibiotic therapy; History of grade II or III septal deviation, nasal polyps, marked turbinate hypertrophy, adenoid hypertrophy, chronic sinusitis (or recent episode within the last 2 weeks), rhinitis (seasonal allergic, drug-induced, vasomotor, atrophic, or other), or other conditions causing nasal obstruction; Diagnosis of: congenital glucose-6-phosphate dehydrogenase deficiency, prothrombin deficiency, gastroduodenal ulcer, hepatic porphyria, narrow-angle glaucoma, chronic nephritis, blood dyscrasias, asthma, chronic respiratory infection, chronic respiratory disease, severe cardiocirculatory conditions, or immunocompromised status; History of hypersensitivity to analgesics, antirheumatic drugs, and/or alcoholic beverages; Participants allergic to foods, hair dyes, and/or preservatives; Participants dependent on decongestants (topical, nasal, or oral) or receiving allergen-specific immunotherapy; Use of monoamine oxidase inhibitors (phenelzine, iproniazid, isocarboxazid, harmaline, nialamide, pargyline, selegiline, toloxatone, tranylcypromine, moclobemide), cyclosporine, chlorpromazine, barbiturates (phenobarbital, thiopental, methohexital, pentobarbital), hypnotics (triazolam, midazolam, oxazepam, chlordiazepoxide, clonazepam), narcotic analgesics (morphine, codeine, meperidine), sedatives, and/or tranquilizers; History of alcoholism (average alcohol intake exceeding 3 standard drinks* in a single day or more than 7 drinks per week for women, and more than 4 drinks in a single day or more than 14 drinks per week for men); One standard drink is defined as: one can of regular beer (330 mL at 4%); one serving of distilled spirits (30 mL at 40%); one glass of wine or small glass of sherry (100 mL at 12% or 70 mL at 18%); one small glass of liqueur or similar (50 mL at 25%); Pregnant or breastfeeding women, or those intending to become pregnant during the study period; Participation in a clinical study within the last 12 months, at the investigator's discretion; Any condition that, in the physician's judgment, may interfere with participation in the study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Common cold/flu or nasal congestion or nasal obstruction

This trial is currently available in Brazil.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Phase III clinical trial to evaluate the efficacy and safety of a fixed-dose combination of 1000 mg dipyrone monohydrate + 60 mg caffeine + 4 mg chlorpheniramine maleate in improving symptoms of the common cold and flu in adults.

The 3 groups in the trial

  • Group ATreatment being tested

    dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg

    Treatment: dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg and Placebo

  • Group BExisting treatment, for comparison

    dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg, coated tablet.

    Treatment: dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg

  • Group CPlacebo, for comparison

    Placebo

    Treatment: Placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Multicenter, Double-blind, Randomized, Parallel-group Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate Compared to Benegrip® in Improving Symptoms of the Common Cold and Flu in Adult Participants
Criteria questions
Built from NCT07626437, who can take part
Record updated
16 June 2026